Shares of Advaxis Inc. (NASDAQ:ADXS) traded up 6.2% on Thursday . The stock traded as high as $8.33 and last traded at $8.04, with a volume of 628,713 shares. The stock had previously closed at $7.57.

Several analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of Advaxis in a research note on Thursday, April 21st. FBR & Co reiterated an “outperform” rating and issued a $34.00 price objective on shares of Advaxis in a research note on Thursday, July 7th. Finally, Jefferies Group reiterated a “buy” rating on shares of Advaxis in a research note on Friday, June 10th. Six equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $24.80.

The company’s 50-day moving average is $8.31 and its 200 day moving average is $7.98. The stock’s market capitalization is $269.27 million.

In related news, CEO Daniel O’connor sold 8,237 shares of the stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $7.51, for a total transaction of $61,859.87. Following the completion of the transaction, the chief executive officer now owns 316,661 shares in the company, valued at $2,378,124.11. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Thomas J. Mckearn sold 4,100 shares of the stock in a transaction dated Friday, May 13th. The shares were sold at an average price of $7.45, for a total transaction of $30,545.00. Following the transaction, the director now owns 82,120 shares of the company’s stock, valued at approximately $611,794. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.